From Fintel and Nasdaq

Neuren Pharmaceuticals (ASX:NEU) Price Target Increased by 5.30% to 20.42

The average one-year price target for Neuren Pharmaceuticals (ASX:NEU) has been revised to 20.42 / share. This is an increase of 5.30% from the prior estimate of 19.40 dated October 31, 2023

The price target is an average of many targets provided by analysts. The latest targets range from a low of 17.17 to a high of 23.93 / share. The average price target represents an increase of 37.07% from the latest reported closing price of 14.90 / share

What is the Fund Sentiment?

There are 25 funds or institutions reporting positions in Neuren Pharmaceuticals. This is an increase of 6 owner(s) or 31.58% in the last quarter. Average portfolio weight of all funds dedicated to NEU is 0.13%, a decrease of 4.72%. Total shares owned by institutions increased in the last three months by 8.99% to 4,880K shares

DISC: Small position Held in SM & RL

Intelligent Investor have just released a research note on NEU (Neuren Pharma: biotech royalty)

They don't have an official buy/hold/sell price target or any other rating on the stock and they aren't officially covering it nor do they plan to at this stage

Their positives essentially align with the discussions already covered here on Strawman. They do also cover a number of possible risks/negatives - e.g. "Neuren only has one product, so any issues discovered after commercialisation could be catastrophic to its royalty stream", the reliance on Acadia (and their limited presence in Europe), and the risk a gene therapy is found for the single gene mutation and actually cures rather than treats the disease